Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center

Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center

BackgroundEculizumab, a terminal complement inhibitor, prevents thrombotic microangiopathy (TMA) and multiorgan damage in hemolytic uremic syndrome (HUS). We evaluated its efficacy and safety in pediatric patients with TMA sub-types: atypical HUS (aHUS), Shiga toxin-producing Escherichia coli (STEC)...

Full description

Saved in:
Bibliographic Details
Main Authors: Naama Lax, Miriam Davidovits, Gabriel Chodick, Yael Bernfeld, Orit Peled
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
eculizumab
hemolytic uremic syndrome
pediatrics
aHUS
STEC-HUS
TA-TMA
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1535407/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1535407/full

Similar Items